Nuzzo, Silvia (2018) Selection of aptamers targeting a hypoxia marker: Carbonic Anhydrase-IX (CA-IX). [Tesi di dottorato]

[img]
Preview
Text
Silvia_Nuzzo_XXX_ciclo_Doctorate_in_Molecular_Medicine_and_Medical_Biotechnology_short_version.pdf

Download (932kB) | Preview
[img] Text
Silvia_Nuzzo_XXX_ciclo_Doctorate_in_Molecular_Medicine_and_Medical_Biotechnology_long_version_.pdf
Visibile a [TBR] Repository staff only fino a 25 July 2020.

Download (2MB) | Request a copy
[error in script] [error in script]
Item Type: Tesi di dottorato
Lingua: English
Title: Selection of aptamers targeting a hypoxia marker: Carbonic Anhydrase-IX (CA-IX)
Creators:
CreatorsEmail
Nuzzo, Silvianuzzo.silvia@gmail.com
Date: 2018
Number of Pages: 94
Institution: Università degli Studi di Napoli Federico II
Department: dep14
Dottorato: phd054
Ciclo di dottorato: 30
Coordinatore del Corso di dottorato:
nomeemail
Avvedimento, Vittorio Enricovittorioenrico.avvedimento@unina.it
Tutor:
nomeemail
de Franciscis, VittorioUNSPECIFIED
Date: 2018
Number of Pages: 94
Uncontrolled Keywords: aptamers, hypoxia
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/04 - Patologia generale
Date Deposited: 27 Dec 2017 23:52
Last Modified: 18 Apr 2019 11:00
URI: http://www.fedoa.unina.it/id/eprint/12248

Abstract

Aptamers are selected by an in vitro combinatorial chemistry approach, named Systematic Evolution of Ligands by Exponential enrichment (SELEX), and they are able to bind with high affinity and specificity virtually any given molecule. Compared to monoclonal antibodies, they have a small size that results in their rapid tumour penetration; they are not immunogenic and could be easily modified to increase their in vivo stability. Thus, in this study we describe the selection of RNA-based aptamers directed against an hypoxic biomarker. Firstly, we performed two different cell-based SELEX protocols that allowed the specific enrichment for the target. Furthermore, we characterized and improved the two best sequences selected, named S-47s1 and S-51s1, that we are still studying to handle a final product usable for diagnostic and therapeutic purposes.

Actions (login required)

View Item View Item